Navigation Links
Bionovo Announces $5 Million Financing
Date:1/3/2012

focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
2. Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
3. Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
4. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
5. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
6. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
7. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
8. Bionovo Announces 2008 Highlights and Year-End Financial Results
9. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
10. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
11. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Fluorescence activated cell sorting (FACS) is a , tool ... individual cells using fluorescent probes that bind specifically to molecules , ... cells of a given population down to the level of a ... Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Isolate and Enrich for ... Isolating Bacterial RNA for Microarray Analysis , The rapid increase in , ... several years has opened up a new ... analysis using DNA microarray technology. In recent , ...
... NEW Cyanobacterial Module , ... MICROB Express (patent pending) is currently the , ... novel strategy that rapidly removes >95% of the 16S and 23S rRNA from , ... species , (Figure 1). MICROB Express can ...
Cached Biology Technology:Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial Whole Genome Array Analysis 2Bacterial Whole Genome Array Analysis 3Bacterial Whole Genome Array Analysis 4Bacterial Whole Genome Array Analysis 5Bacterial Whole Genome Array Analysis 6Bacterial Whole Genome Array Analysis 7Bacterial mRNA Isolation, Fast and Easy 2Bacterial mRNA Isolation, Fast and Easy 3
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... a recent academic review, a University of Minnesota professor in ... opposed to specific nutrients, may be key to having a ... in food industry and government, where marketers and regulators tend ... specific vitamins and added supplements in food products, not the ...
... and EUMETSAT, the European Organisation for the Exploitation ... provide essential launch control services for the last ... MSG-4. Under the agreement, ESA will provide ... orbit phase (LEOP), which involves moving the satellite ...
... P&G Beauty announced that they successfully sequenced the complete ... naturally occurring fungus responsible for the onset of dandruff ... the genome sequencing are published in todays online edition ... Dandruff and seborrheic dermatitis affect more than 50 ...
Cached Biology News:Foods, not specific nutrients, may be key to good health 2ESA to provide essential launch control services to EUMETSAT 2ESA to provide essential launch control services to EUMETSAT 3Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 2Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 3
... emerging as a powerful new tool for ... only amino groups have been able to ... as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and its ... to the protein interaction tool chest that ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: